Impact of subjective sleep quality on glycemic control in type 2 diabetes mellitus. 2012

Yi-Wen Tsai, and Nai-Hsuan Kann, and Tao-Hsin Tung, and Yi-Jen Chao, and Chin-Jung Lin, and Ko-Chen Chang, and Shy-Shin Chang, and Jau-Yuan Chen
Department of Family Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan.

BACKGROUND Glycaemic control is fundamental to the management of and risk reduction in microvascular complications of diabetes. OBJECTIVE The aim of this study was to investigate the association of sleep quality with glycaemic control and its impact on type 2 diabetic patients in an Asian population. METHODS A total of 46 subjects with type 2 diabetes mellitus were enrolled. HbA1C was measured in each patient, and each patient completed the Chinese version of the Pittsburgh Sleep Quality Index (PSQI) questionnaire. Good sleep quality was defined as PSQI score ≤5. RESULTS After adjusting for age, gender and body mass index, the total PSQI score and sleep efficiency (P < 0.05) were significantly correlated with the level of HbA1C. Logistic regression analysis showed the adjusted odds ratio (OR) of sleep efficiency for HbA1C level was 6.83 [OR = 6.83, 95% confidence interval (CI) = 2.04-22.8, P = 0.002]. The adjusted ORs of worse glycaemic control for the poor sleep quality group was 6.94 with regard to the group of good sleep quality (OR = 6.94, 95% CI: 1.02-47.16, P < 0.05). CONCLUSIONS This study demonstrated that both poor sleep quality and less-efficient sleep are significantly correlated with worse glycaemic control in patients with type 2 diabetes. These findings are expected to contribute to the prevention and risk reduction of microvascular complications in type 2 diabetes.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011788 Quality of Life A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral, social environment as well as health and disease. HRQOL,Health-Related Quality Of Life,Life Quality,Health Related Quality Of Life
D011795 Surveys and Questionnaires Collections of data obtained from voluntary subjects. The information usually takes the form of answers to questions, or suggestions. Community Survey,Nonrespondent,Questionnaire,Questionnaires,Respondent,Survey,Survey Method,Survey Methods,Surveys,Baseline Survey,Community Surveys,Methodology, Survey,Nonrespondents,Questionnaire Design,Randomized Response Technique,Repeated Rounds of Survey,Respondents,Survey Methodology,Baseline Surveys,Design, Questionnaire,Designs, Questionnaire,Methods, Survey,Questionnaire Designs,Questionnaires and Surveys,Randomized Response Techniques,Response Technique, Randomized,Response Techniques, Randomized,Survey, Baseline,Survey, Community,Surveys, Baseline,Surveys, Community,Techniques, Randomized Response
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females

Related Publications

Yi-Wen Tsai, and Nai-Hsuan Kann, and Tao-Hsin Tung, and Yi-Jen Chao, and Chin-Jung Lin, and Ko-Chen Chang, and Shy-Shin Chang, and Jau-Yuan Chen
January 2014, Chinese medical journal,
Yi-Wen Tsai, and Nai-Hsuan Kann, and Tao-Hsin Tung, and Yi-Jen Chao, and Chin-Jung Lin, and Ko-Chen Chang, and Shy-Shin Chang, and Jau-Yuan Chen
November 1998, Medicine and health, Rhode Island,
Yi-Wen Tsai, and Nai-Hsuan Kann, and Tao-Hsin Tung, and Yi-Jen Chao, and Chin-Jung Lin, and Ko-Chen Chang, and Shy-Shin Chang, and Jau-Yuan Chen
March 2016, Circulation. Cardiovascular imaging,
Yi-Wen Tsai, and Nai-Hsuan Kann, and Tao-Hsin Tung, and Yi-Jen Chao, and Chin-Jung Lin, and Ko-Chen Chang, and Shy-Shin Chang, and Jau-Yuan Chen
March 2024, Scientific reports,
Yi-Wen Tsai, and Nai-Hsuan Kann, and Tao-Hsin Tung, and Yi-Jen Chao, and Chin-Jung Lin, and Ko-Chen Chang, and Shy-Shin Chang, and Jau-Yuan Chen
January 2020, Kathmandu University medical journal (KUMJ),
Yi-Wen Tsai, and Nai-Hsuan Kann, and Tao-Hsin Tung, and Yi-Jen Chao, and Chin-Jung Lin, and Ko-Chen Chang, and Shy-Shin Chang, and Jau-Yuan Chen
November 2016, Journal of general internal medicine,
Yi-Wen Tsai, and Nai-Hsuan Kann, and Tao-Hsin Tung, and Yi-Jen Chao, and Chin-Jung Lin, and Ko-Chen Chang, and Shy-Shin Chang, and Jau-Yuan Chen
November 2013, Indian journal of endocrinology and metabolism,
Yi-Wen Tsai, and Nai-Hsuan Kann, and Tao-Hsin Tung, and Yi-Jen Chao, and Chin-Jung Lin, and Ko-Chen Chang, and Shy-Shin Chang, and Jau-Yuan Chen
November 2016, Iranian journal of medical sciences,
Yi-Wen Tsai, and Nai-Hsuan Kann, and Tao-Hsin Tung, and Yi-Jen Chao, and Chin-Jung Lin, and Ko-Chen Chang, and Shy-Shin Chang, and Jau-Yuan Chen
November 2022, Scientific reports,
Yi-Wen Tsai, and Nai-Hsuan Kann, and Tao-Hsin Tung, and Yi-Jen Chao, and Chin-Jung Lin, and Ko-Chen Chang, and Shy-Shin Chang, and Jau-Yuan Chen
May 2023, European review for medical and pharmacological sciences,
Copied contents to your clipboard!